Joshua Brumm
2018 - Kaleido Biosciences
In 2018, Joshua Brumm earned a total compensation of $2.9M as Chief Operating Officer and Chief Financial Officer former principal financial officer at Kaleido Biosciences.
Compensation breakdown
| Non-Equity Incentive Plan | $126,138 |
|---|---|
| Option Awards | $2,107,576 |
| Salary | $296,891 |
| Other | $320,586 |
| Total | $2,851,191 |
Brumm received $2.1M in option awards, accounting for 74% of the total pay in 2018.
Brumm also received $126.1K in non-equity incentive plan, $296.9K in salary and $320.6K in other compensation.
Rankings
In 2018, Joshua Brumm's compensation ranked 4,083rd out of 14,244 executives tracked by ExecPay. In other words, Brumm earned more than 71.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,083 out of 14,244 | 71st |
Division Manufacturing | 1,505 out of 5,765 | 74th |
Major group Chemicals And Allied Products | 535 out of 2,128 | 75th |
Industry group Drugs | 447 out of 1,817 | 75th |
Industry Biological Products, Except Diagnostic Substances | 92 out of 339 | 73rd |
Source: SEC filing on May 8, 2020.
Brumm's colleagues
We found two more compensation records of executives who worked with Joshua Brumm at Kaleido Biosciences in 2018.
News
Dyne Therapeutics CEO Joshua Brumm's 2022 pay rises 6% to $4.3M
April 7, 2023
Dyne Therapeutics CEO Joshua Brumm's 2021 pay falls 66% to $4.1M
April 22, 2022
Dyne Therapeutics CEO Joshua Brumm's 2020 pay jumps 981% to $12M
April 14, 2021
Kaleido Biosciences CEO Alison Lawton's 2019 pay falls 57% to $2.9M
May 8, 2020